Phuong Khanh Morrow: FDA Approval Marks an Important Step Forward for the PV Community
Phuong Khanh Morrow, Board Member of Reagan-Udall Foundation for the FDA, Senior Vice President and Head of Oncology Therapeutic Area Unit (OTAU) at Takeda, Board Member of Lantheus, shared a post on LinkedIn:
“Patients living with PV often have limited treatment options to help them manage this chronic and difficult blood cancer. This shines a light on the pressing need for additional treatment options.
As an oncologist, an FDA approval is never just a milestone – it’s a moment where science meets real possibility for patients!
This approval represents an important step forward for the PV community.
Progress like this underscores why continued scientific innovation matters and why we remain focused on advancing options that can make a meaningful difference for patients!”
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge
-
Oct 19, 2026, 16:13Javier M. Floren: When Immune Cells Move With Their Environment